Abstract 1161P
Background
Therapeutic options for advanced melanoma patients (pts) resistant to standard treatment (Tx): immunotherapy & anti-BRAF-based targeted therapy represent a high medical need. Objective: Our aim was to evaluate the applicability of precision medicine in melanoma pts who failed standard tx based on molecular profiling (MP) of their tumors & the resulting clinical outcome.
Methods
All pts with advanced melanoma resistant to standard tx who had a MP at Gustave Roussy between April 2021 & March 2023 were included in this retrospective study. MP was performed by using Next Generation sequencing by using Foundation one CDX/liquidCDX & it was based on 3 protocols: STING (NCT04932525), MCLA-128 (NCT03321981) & STARTRK (NCT02568267) which allowed liquid & tissue biopsies studies. Molecular actionability was based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) classification.
Results
We performed MP for 184 pts: 174 had melanoma, 2 pts with EWSR1-ATF1 fusion & 1 with EWSR1-CREB1, which allowed a diagnosis correction to clear cell sarcoma & the initiation of the appropriate sarcoma tx, 3 BCC, 3 cSCC & 1 Merkel cell cancer. For the 174 melanoma pts, apart from the BRAF V600 mutation (50% of the pts), a putative actionable molecular orientation was found in 51.6% of the pts. The most frequent molecular alterations were: NRAS (23.2%), PTEN (12.6%), ATM (8.4%), CDKN2A (7.4%), BRAF class II (6.3%), BRAF class III (5.3%), KIT (4.2%) PIK3CA (3.2%), MAP2K1 (3.2%), NF1 (2.1%), AKT (1.1%), HRAS (1.1%), MET (1.1%), ALK (1.1%), ARID1A (1.1%), CDK4 (1.1%), CCND1 (1.1%). Molecularly matched tx was administered to 15 pts: anti-MEK (n = 11) & imatinib (n = 2). Among the 11 pts on anti-MEK, 1 partial response was seen after 9 months of tx & the remaining 10 pts rapidly progressed after 1-3 months of anti-MEK tx as for the 2 pts on imatinib. Unfortunately, no precision medicine tx was available to target the other potentially actionable mutations at the time they were needed.
Conclusions
Potentially actionable mutations can be found in more than 50% of pts with resistant melanoma. Tumor agnostic trials based on molecular alterations should be more broadly available to evaluate the potential benefit of innovative precision medicine in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13